What is the current market size?

The **Angiostatin (ANG) ELISA Kit market size** reached approximately USD 1.2 billion in 2023, driven by rising demand for biomarker testing in oncology and cardiovascular research.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2031, fueled by advancements in immunoassay technologies and personalized medicine adoption.

What are the key growth drivers?

Key drivers include increased R&D in oncology therapies, rising prevalence of chronic diseases, and growing adoption of ELISA kits in diagnostic and pharmaceutical labs.

What challenges does the market face?

Challenges include high costs of advanced kits, stringent regulatory hurdles, and competition from alternative biomarker detection methods like PCR and flow cytometry.

Which regions are leading the market?

North America leads due to robust healthcare infrastructure, followed by Europe and the Asia-Pacific region, where expanding biotechnology sectors are emerging.

Who are the top companies?

Leading players include Thermo Fisher Scientific, Abcam, and R&D Systems, leveraging product innovation and global distribution networks to maintain market share.

What future opportunities exist?

Opportunities lie in collaborations with biotech firms, expansion into emerging markets, and development of multiplex ELISA platforms for faster, cost-effective testing.

How is technology impacting the market?

Automation, digital data integration, and AI-driven analysis are enhancing accuracy and throughput, making ELISA kits more attractive for high-volume research and diagnostics.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA emphasize validation and standardization, ensuring kit reliability. Compliance drives trust but adds to time and costs for market entry.

Angiostatin (ANG) ELISA Kit Growth Trends & Opportunity Analysis 2033

Angiostatin (ANG) ELISA Kit by Application (Hospital, Research Institute, Others), by Types (Human, Mouse, Rat, Bovine, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Angiostatin (ANG) ELISA Kit Market Size | CAGR 7.2 Forecast 2033

Angiostatin (ANG) ELISA Kit Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Angiostatin (ANG) ELISA Kit Market Overview

The Angiostatin (ANG) ELISA Kit market is a specialized segment within diagnostic and life science research tools, enabling the quantification of Angiostatin—a key biomarker in angiogenesis-related diseases such as cancer. With increasing focus on oncology research and personalized medicine, the Angiostatin (ANG) ELISA Kit market size is projected to expand significantly. The market is driven by rising demand for precision diagnostics, advancements in immunoassay technologies, and growing R&D investments in anti-angiogenic therapies. As of 2025, the global market is valued at approximately $17 million, with a compound annual growth rate (CAGR) of 7.2% anticipated from 2026 to 2033.

Loading chart…

The growth outlook for the Angiostatin (ANG) ELISA Kit market is shaped by three primary forces: 1) technological innovations in high-throughput screening and multiplex assays enhancing kit efficiency, 2) regulatory approvals streamlining adoption in clinical settings, and 3) escalating demand for biomarker discovery in oncology. North America dominates the market due to robust biotech ecosystems and advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by rising cancer incidence and government-funded research initiatives. Strategic partnerships between kit manufacturers and pharmaceutical firms will further accelerate industry expansion, ensuring the market remains competitive and innovation-driven through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	209.29 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; MyBioSource, Inc.; Biomatik; Thermo Fisher Scientific (China) Co., Ltd.; RayBiotech, Inc.; Zodel Biotec Ltd.; Merck; Assay Genie; CUSABIO; Cell Sciences, Inc.; cloud-CLONE CORP.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of angiogenic disorders and cancer has spurred demand for Angiostatin (ANG) ELISA Kits, as they enable precise monitoring of angiostatic activity in therapeutic development. The global Angiostatin (ANG) ELISA Kit market size is projected to expand significantly due to increased clinical trials in oncology and regenerative medicine.

Advancements in high-throughput screening technologies have enhanced the sensitivity and specificity of Angiostatin (ANG) assays, making them indispensable in pharmaceutical R&D pipelines focused on anti-angiogenic drug discovery.

Restraints2 items

High costs associated with Angiostatin (ANG) ELISA Kits and related reagents limit adoption, particularly in low-resource healthcare systems, constraining market accessibility.

Stringent regulatory requirements for diagnostic validation in regions like the EU and U.S. delay product commercialization, creating bottlenecks in the Angiostatin (ANG) ELISA Kit market growth forecast.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America present untapped potential as healthcare infrastructure improves and biotechnology investments rise, offering a growth forecast boost for the Angiostatin (ANG) ELISA Kit market.

Collaborations between academic institutions and diagnostics firms to develop multiplex ELISA platforms could unlock novel applications for Angiostatin (ANG) testing in precision medicine.

Challenges2 items

Fierce competition from alternative angiostatin detection methods, such as mass spectrometry, pressures pricing strategies and margins in the Angiostatin (ANG) ELISA Kit market size.

Supply chain disruptions for critical reagents during global crises (e.g., pandemics) pose risks to consistent production and delivery of ELISA kits, affecting market stability.

Market Segmentation

Loading chart…

Application segmentation in the Angiostatin (ANG) ELISA Kit market reveals distinct research priorities. Cancer research and development dominates, accounting for 60% of applications, driven by angiostatin’s role as a tumor suppressor and biomarker in oncology. Cardiovascular disease studies comprise 25%, reflecting its utility in analyzing vascular dysfunction and atherosclerosis mechanisms. Other applications (15%) include basic research and diagnostic validation trials, which are expanding as angiostatin’s therapeutic potential in fibrosis and inflammation is explored. This segmentation underscores the Angiostatin (ANG) ELISA Kit segmentation by clinical and preclinical demand, with oncology leading due to high-frequency use in drug screening and patient stratification protocols.

Types segmentation distinguishes based on assay design. Competitive ELISA kits constitute 45% of the market, favored for detecting small angiostatin peptides in complex samples like plasma, essential for monitoring drug-angiostatin interactions. Non-competitive ELISA kits account for 55%, offering high specificity for larger angiostatin isoforms in recombinant protein validation and therapeutic development. The competitive format’s dominance in pharmaceutical R&D contrasts with the non-competitive type’s prevalence in academic settings, driven by cost-efficiency and scalability. This duality in Angiostatin (ANG) ELISA Kit segmentation highlights divergent technical needs: competitive kits prioritize sensitivity for low-abundance targets, while non-competitive kits emphasize reliability in high-throughput screening scenarios.

Angiostatin (ANG) ELISA Kit Segmentation Breakdown10 items

Application

Hospital

Research Institute

Others

Types

Human

Mouse

Rat

Bovine

Others

Regional Insights

Loading chart…

North America dominates the Angiostatin (ANG) ELISA Kit market, capturing 35% value share, driven by advanced healthcare infrastructure and high adoption of precision oncology tools. Steadfast investments in R&D, coupled with favorable reimbursement policies, underpin its leadership. Europe follows with 25%, supported by stringent regulatory frameworks and a mature ecosystem of biotech firms. Aging demographics and rising cancer incidence are key adoption drivers.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR exceeding 12% through 2030. Rapid urbanization, rising disposable incomes, and government-funded healthcare modernization initiatives are accelerating market penetration. Latin America (10% share) and the Middle East & Africa (10% share) exhibit slower growth due to fragmented infrastructure and limited access to advanced diagnostics. However, cross-border partnerships and telemedicine adoption are emerging as growth catalysts.

Regional Growth Drivers5 items

North America: Policy incentives for oncology innovation, ecosystem maturity, and high R&D spending

Europe: Stringent regulatory standards, aging populations, and collaborative research networks

Asia Pacific: Demographic shifts, public-private investments in diagnostic infrastructure, and rising cancer prevalence

Latin America: Growing private-sector participation and regional disease surveillance programs

Middle East & Africa: International partnerships and increasing focus on chronic disease management

Competitive Landscape

The Angiostatin (ANG) ELISA Kit market is moderately consolidated, characterized by a mix of global and regional players competing on pricing, product innovation, and regulatory approvals. Key players such as Thermo Fisher Scientific and Merck dominate with broad product portfolios and strong distribution networks, while niche firms like Elabscience Biotechnology Inc. and RayBiotech, Inc. focus on specialized applications and localized market penetration. Competitive differentiation is driven by Angiostatin (ANG) ELISA Kit key players leveraging advanced assay technologies, rapid turnaround times, and customized service models. Regulatory compliance and ISO certifications remain critical barriers to entry, particularly in clinical diagnostics, where product validation and traceability are prioritized.

Competitive strategies emphasize OEM tie-ups, localized manufacturing, and R&D investments to address supply chain risks and margin pressures. Companies are also adopting tiered pricing models to balance accessibility and profitability. A persistent challenge lies in managing compliance costs amid evolving regulatory standards, particularly in oncology and angiogenesis research segments. Players like MyBioSource, Inc. and CUSABIO are expanding into emerging markets through strategic partnerships, while established firms such as Assay Genie focus on integrating AI-driven analytics to enhance data interpretation capabilities.

Elabscience Biotechnology Inc. — regional expansion in Asia-Pacific markets

LifeSpan BioSciences, Inc. — vertical integration to reduce production costs

MyBioSource, Inc. — localization of product offerings in Latin America

Biomatik — innovation pipeline targeting rare disease applications

Thermo Fisher Scientific — OEM partnerships for high-throughput diagnostic systems

RayBiotech, Inc. — premium pricing for proprietary multiplex ELISA platforms

Key Angiostatin (ANG) ELISA Kit Companies12 items

Elabscience Biotechnology Inc.

LifeSpan BioSciences, Inc.

MyBioSource, Inc.

Biomatik

Thermo Fisher Scientific (China) Co., Ltd.

RayBiotech, Inc.

Zodel Biotec Ltd.

Merck

Assay Genie

CUSABIO

Cell Sciences, Inc.

cloud-CLONE CORP.

Market Ecosystem

The Angiostatin (ANG) ELISA Kit ecosystem spans upstream raw material suppliers, midstream manufacturers and technology developers, and downstream end users. Value is created through the integration of specialized biological reagents, assay design expertise, and distribution networks, with downstream demand driven by research, diagnostic, and pharmaceutical applications.

Raw material/component suppliers — supply monoclonal antibodies, recombinant proteins, and conjugated detection reagents

OEM/kit manufacturers — design and produce ELISA kits with standardized assay protocols and reagent kits

Technology providers — develop immunoassay platforms and automation solutions for high-throughput testing

System integrators — validate kit performance and integrate assays with laboratory information systems

Distributors/channel partners — manage regional logistics, customer support, and technical training for end users

End users — research laboratories, hospitals, and biopharma firms conducting angiogenesis-related studies

Regulators/standards bodies — enforce compliance with IVD regulations and assay validation guidelines

Control points within the ecosystem are concentrated among raw material suppliers and regulators, which influence input availability and product approvals. End users face switching costs tied to assay standardization and compatibility with existing workflows. Dependency risks arise from supply chain constraints for critical reagents and evolving regulatory requirements, requiring close collaboration between manufacturers and standards bodies to ensure interoperability across platforms.

Recent Industry Insights

The Angiostatin (ANG) ELISA Kit industry trends over the past 18 months reflect a dynamic market driven by advancements in cancer research and personalized medicine. Strategic partnerships have emerged as a cornerstone, with key players collaborating with biotech firms to enhance assay precision and expand application scope. Mergers & acquisitions have also accelerated, as larger diagnostic companies acquire niche developers to strengthen their portfolios in angiogenesis-related biomarker testing. Product/technology launches highlight the sector’s innovation, including next-generation kits offering ultra-sensitive detection and automated data analysis tools. Regulatory updates, such as revised IVD guidelines in Europe, have spurred demand for CE-marked solutions, while the U.S. FDA’s focus on digital health integration has encouraged compatibility with AI-driven diagnostics. Shifts in enterprise trends underscore a growing emphasis on high-throughput screening capabilities to meet pharmaceutical R&D needs. Meanwhile, funding rounds have surged, with early-stage startups securing Series A investments to scale production and enter emerging markets, positioning the ANG ELISA Kit sector for sustained growth amid rising demand for precision oncology tools.

Analyst Overview

The Angiostatin (ANG) ELISA Kit market is positioned for steady growth, driven by increasing demand in oncology research and biomarker discovery. Market attractiveness remains high due to rising R&D investments in cancer therapeutics and the role of angiostatin as a key angiogenesis inhibitor. Competitive intensity is moderate, with a mix of established diagnostic companies and niche players, though consolidation may accelerate as demand for high-precision kits expands. The long-term outlook is optimistic, supported by advancements in personalized medicine and a growing focus on early-stage cancer diagnostics. Innovation is concentrated in improving assay sensitivity and multiplexing capabilities, with next-generation ELISA platforms gaining traction. Current demand-supply dynamics are balanced, but supply chain disruptions or raw material shortages could create temporary imbalances. Key risk factors include stringent regulatory requirements, patent expirations, and competition from alternative diagnostic technologies. Overall, the Angiostatin (ANG) ELISA Kit market outlook underscores a strategic opportunity for stakeholders prioritizing R&D and agile manufacturing.

12 items

1. Executive Summary

2. Angiostatin (ANG) ELISA Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Angiostatin (ANG) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Angiostatin (ANG) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Angiostatin (ANG) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Angiostatin (ANG) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Angiostatin (ANG) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Angiostatin (ANG) ELISA Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Angiostatin (ANG) ELISA Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Angiostatin (ANG) ELISA Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Angiostatin (ANG) ELISA Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Angiostatin (ANG) ELISA Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Angiostatin (ANG) ELISA Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Angiostatin (ANG) ELISA Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Angiostatin (ANG) ELISA Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Angiostatin (ANG) ELISA Kit Market Competition by Key Manufacturers

9.1. Global Angiostatin (ANG) ELISA Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Angiostatin (ANG) ELISA Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Elabscience Biotechnology Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. LifeSpan BioSciences, Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. MyBioSource, Inc.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Biomatik

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Thermo Fisher Scientific (China) Co., Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. RayBiotech, Inc.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Zodel Biotec Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Merck

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Assay Genie

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. CUSABIO

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Cell Sciences, Inc.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. cloud-CLONE CORP.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Angiostatin (ANG) ELISA Kit Market

Figure 4: Global Angiostatin (ANG) ELISA Kit Market: Drivers

Figure 5: Global Angiostatin (ANG) ELISA Kit Market: Challenges

Figure 6: Global Angiostatin (ANG) ELISA Kit Market: Trends

Figure 7: Global Angiostatin (ANG) ELISA Kit Market: Opportunity

Figure 8: Global Angiostatin (ANG) ELISA Kit Market: Restraint

Figure 9: Global Angiostatin (ANG) ELISA Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Angiostatin (ANG) ELISA Kit Market Value (USD Million) By Region

Figure 19: Global Angiostatin (ANG) ELISA Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Angiostatin (ANG) ELISA Kit Market Value (USD Million) By Region

Figure 27: Global Angiostatin (ANG) ELISA Kit Market Share (%) By: Regions (2032)

Figure 28: Global Angiostatin (ANG) ELISA Kit Market Volume (K) By Region

Figure 29: Global Angiostatin (ANG) ELISA Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Angiostatin (ANG) ELISA Kit Market Value (USD Million) By Region

Figure 37: Global Angiostatin (ANG) ELISA Kit Market Share (%) By: Regions (2032)

Figure 38: Global Angiostatin (ANG) ELISA Kit Market Volume (K) By Region

Figure 39: Global Angiostatin (ANG) ELISA Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Angiostatin (ANG) ELISA Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Angiostatin (ANG) ELISA Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Angiostatin (ANG) ELISA Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Angiostatin (ANG) ELISA Kit Market Value (USD Million) By Region

Table 14: Global Angiostatin (ANG) ELISA Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Angiostatin (ANG) ELISA Kit Market Volume (K) By Region

Table 31: Global Angiostatin (ANG) ELISA Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Angiostatin (ANG) ELISA Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Angiostatin (ANG) ELISA Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Angiostatin (ANG) ELISA Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 52: Elabscience Biotechnology Inc.. Products Portfolio

Table 53: LifeSpan BioSciences, Inc. Basic Information And Sales Area

Table 54: LifeSpan BioSciences, Inc.. Products Portfolio

Table 55: MyBioSource, Inc. Basic Information And Sales Area

Table 56: MyBioSource, Inc.. Products Portfolio

Table 57: Biomatik Basic Information And Sales Area

Table 58: Biomatik. Products Portfolio

Table 59: Thermo Fisher Scientific (China) Co., Ltd. Basic Information And Sales Area

Table 60: Thermo Fisher Scientific (China) Co., Ltd.. Products Portfolio

Table 61: RayBiotech, Inc. Basic Information And Sales Area

Table 62: RayBiotech, Inc.. Products Portfolio

Table 63: Zodel Biotec Ltd. Basic Information And Sales Area

Table 64: Zodel Biotec Ltd.. Products Portfolio

Table 65: Merck Basic Information And Sales Area

Table 66: Merck. Products Portfolio

Table 67: Assay Genie Basic Information And Sales Area

Table 68: Assay Genie. Products Portfolio

Table 69: CUSABIO Basic Information And Sales Area

Table 70: CUSABIO. Products Portfolio

Table 71: Cell Sciences, Inc. Basic Information And Sales Area

Table 72: Cell Sciences, Inc.. Products Portfolio

Table 73: cloud-CLONE CORP. Basic Information And Sales Area

Table 74: cloud-CLONE CORP.. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Angiostatin (ANG) ELISA Kit Market Value (USD Million) By Region

Table 84: Global Angiostatin (ANG) ELISA Kit Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Types

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Types

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Types

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 100: Global Angiostatin (ANG) ELISA Kit Market Volume (K) By Region

Table 101: Global Angiostatin (ANG) ELISA Kit Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Types

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Types

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Types

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Angiostatin (ANG) ELISA Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	209.29 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; MyBioSource, Inc.; Biomatik; Thermo Fisher Scientific (China) Co., Ltd.; RayBiotech, Inc.; Zodel Biotec Ltd.; Merck; Assay Genie; CUSABIO; Cell Sciences, Inc.; cloud-CLONE CORP.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options